Generic drug maker Mylan Inc., which early next year expects to cut its corporate tax bill by reincorporating in the Netherlands, will pay its top four executives some $30.4 million ahead of schedule so they can avoid special taxes related to the controversial practice known as an inversion, according to a regulatory filing.
Under the plan, the Cecil-based company will accelerate the vesting of certain equity-based awards, such as stock options, so the executives aren’t hit with an excise tax that’s meant to discourage inversions, according to the filing with the U.S. Securities and Exchange Commission.
It was unclear when the awards normally would have vested.
Mylan did not respond to emails seeking comment.
The company will spend another $19.5 million to reimburse the executives for excise taxes they will owe on certain other awards, the filing said, bringing the total payout to approximately $50 million. The penalty tax covers certain equity awards held by the executives at the time of the inversion transaction, which will be undertaken as part of Mylan’s purchase of a major chunk of Chicago-based Abbott Laboratories’ generic business overseas.
Mylan’s directors also will receive accelerated payouts and tax reimbursements under the plan, the filing said.
Read More
The drug maker’s board approved the payouts because the executives and directors “were critically important to Mylan’s past success and in negotiating this transformative opportunity,” the company said in the filing.
Chairman Robert Coury’s accelerated awards were valued at $10.7 million. He also is set to receive $3.8 million in tax reimbursements, for a total payout of about $14.5 million.
CEO Heather Bresch’s total payout was valued at $15.8 million, which includes $10.5 million in accelerated awards and $5.3 million for her tax bill.
Mylan shareholders will be asked to approve the proposed inversion, which is expected to be completed in the first quarter next year, at a special meeting. The date for the special meeting has not been announced.
At the same time, shareholders will be asked to vote on the executive payouts related to the inversion, but that vote will be nonbinding.
If the inversion is approved and completed, “The [executive] compensation will be payable regardless of the outcome of the vote to approve such compensation,” the filing said.
Mylan has said the inversion was expected to lower its adjusted tax rate from about 25 percent to the high teens over time.
Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.